Audit: QRS - GHRP-6 for Health & Longevity
Audit conducted on 07/08/2026 08:47 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 81 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol cells (100 µg SC, 2–3× daily, empty stomach), time-to-effect values (30–45 min, 20–30 min, 8–12 weeks), all benefit/risk tier entries, all 12 contraindications, all 12 interactions, all 9 biomarkers with targets, cadence, and all 9 qualitative markers trace to ER lines 396–404, 451, 153–213, 237–303, 323–362, 481–501. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | At-a-glance retains “That pulse is well established; almost everything beyond it is unresolved” from ER Conclusion (line 527); no hedged ER statement is rendered as settled. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | “Pregnancy and lactation” and “Recombinant human growth hormone” remain absolute stop items, matching ER lines 341 and 360. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications and Key Interactions both derive from the ER Key Interactions & Contraindications section only; no Benefit- or Risk-Modifying Factor content is surfaced as a gate item. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, author names, or trial names appear anywhere in the QRS; all named drugs (octreotide, semaglutide, MK-677, etc.) appear in the ER for the same interaction. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Sober, evidence-weighted register matching the ER; the at-a-glance mirrors the ER Conclusion’s balance of established pulse against unresolved downstream effects. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Presents thresholds, targets, and tiers without alarmism or exhortation; content is decision-enabling. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | No imperatives directed at a patient; sections describe what is measured and what is documented. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Gate and monitoring entries are stated as facts and ranges, not instructions. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommended”, “should”, or “advised” constructions in the populated spans. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained (Child-Pugh Class C, apnea-hypopnea index, prednisone-equivalent) are the threshold qualifiers required by items 8.5/9.5, not gratuitous jargon. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Benefits and risks are reduced to bare tier headings; gate items carry no rationale; protocol subs are one sentence each. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address in any span. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional biomarker targets (fasting insulin 2–5 µIU/mL, HbA1c 4.8–5.3%) and third-party verification framing address exactly this audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | 2–3× daily fasted subcutaneous dosing, 9-marker panel, and weekly waist measurement assume a high-effort audience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content depth and monitoring burden are well beyond a general-population sheet. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Appetite stimulation appears as a Medium benefit and simultaneously as the leading High risk, reflecting the ER’s point that the effect is unwanted for body-composition-conscious adults. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the speculative benefit uses “biological aging”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “subcutaneously”, “peripheral edema”, “receptor desensitization”, “cytoprotection” used throughout; the plain-language rendering in the at-a-glance is mandated by item 7.4 and taken from the ER Conclusion. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fourteen fixed strings verified byte-identical to the template at QRS lines 444, 484, 529, 554, 578, 607, 632, 636–638, 767. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template span names present; the repeatable marker_#_* and qualitative_item_# spans are expanded to 9 instances each as designed. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Structural diff against the template shows the CSS block byte-identical and only the metadata block plus expected span content changed; <span website="evidence_review">, <span website="audit">, <span website="full_review">, and the footer disclaimer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section drawn on by the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Monitoring row labels (“IGF-1”, “IGF binding protein 3”, “Morning cortisol”, “TSH and free T4”, “Apolipoprotein B”) are the ER biomarker table’s own labels verbatim (ER lines 481–489). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker names and tier labels match the ER; protocol and time-to-effect cell labels are the standard fixed template cell labels populated per items 10.2 and 11.1. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters occur in the file; the ER’s 🟩/🟥/🟨 tier markers and ⚠️ Conflicted flags were correctly stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to its checklist floor: benefits and risks are bare tier headings with all parentheticals stripped, gate items carry no rationale or trailing clauses, protocol subs are single sentences, and the cadence is a single compressed line. Remaining length is driven entirely by the completeness requirements of items 8.2, 9.2, 14.2, and 15.2, which forbid dropping items. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html> on line 1 and before the template’s own comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13; the lead-in text on line 2 precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed entirely in an HTML comment; no metadata value is repeated in the header, footer, or any span. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, and it contains a colon requiring YAML quoting; all other values are bare and trimmed. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: ghrp_6_2026-0807-0333_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0807-0837, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version only, no context-window or tier qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: ghrp_6_2026-0807-0333_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys including git_user and git_issue; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: GHRP-6 for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: GHRP-6 for Health & Longevity. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 08/07/2026, correctly derived from qrs_creation_date: 2026-0807-0837. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only the title and the template subline; the ER’s long “Also known as” list was correctly not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER lines 527–531 into mechanism, evidence status, dominant adverse effects, and the source-concentration caveat. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Mechanism → ER line 527; “well established / unresolved” → line 527; hunger, stress hormone, blood sugar, fluid retention → line 529 and Risks headings at lines 237–259; single institute → line 531. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “ghrelin” rendered as “the stomach’s hunger hormone”, “GHS-R1a”/”cortisol” avoided in favour of “stress-hormone output”, “glucose” as “blood sugar”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes, or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric effect sizes or statistics of any kind. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All 12 stop items map to ER lines 323, 341, and 353–362. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All ten entries of the ER’s “Populations who should avoid this intervention” list plus the two absolute-avoid drug interactions (recombinant human growth hormone, somatostatin analogues) are present. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Twelve discrete <li> elements at QRS lines 557–573. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | ER rationales stripped throughout (e.g., “given the mitogenic profile of IGF-1”, “where no safety data of any kind exist”, “since growth hormone secretagogues are prohibited… under class S2”); no dash-trailing clauses remain. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “remission for less than 5 years”, “hemoglobin A1c above 7.5% or fasting glucose persistently above 126 mg/dL”, “apnea-hypopnea index of 15 or more events per hour”, “roughly 7.5 mg prednisone-equivalent daily”, “Child-Pugh Class C”, “New York Heart Association Class IV” all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its contraindication entries. |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | Stop items are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All 12 caution items map to ER lines 325–349. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All 12 remaining ER interaction bullets are present; somatostatin analogues and recombinant human growth hormone are correctly excluded here as they sit in Contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Twelve discrete <li> elements at QRS lines 581–597. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s “— caution, glycaemic instability”, “— monitor, altered response”, “— caution, synergistic hormone release” trailing clauses are all stripped; no mechanism or mitigation text carried over. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Every ER example-drug list is retained verbatim (prednisone/dexamethasone/hydrocortisone; glipizide/glimepiride/insulin itself; semaglutide/tirzepatide/liraglutide; risperidone/haloperidol/metoclopramide/amisulpride; sermorelin/tesamorelin/CJC-1295/ipamorelin/MK-677; levothyroxine/liothyronine; ibuprofen/naproxen; the three supplement lists). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its interaction entries. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | Caution items are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from ER Therapeutic Protocol lines 396–410 plus the mitigation parameters at lines 369–373. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose (100 µg subcutaneously), Frequency (2–3× daily), and Timing (empty stomach) are the three parameters the ER’s dominant pulsatile-secretagogue protocol is built on. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct actionable aspects are present; no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans populated; subs carry the saturation rationale (ER line 396), the cycling pattern (line 396), and the fasted-state priority (lines 396, 404). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Growth hormone pulse, appetite surge, and body composition — the three outcome-bearing timelines in ER line 451; the IGF-1 steady-state interval is folded into the third sub. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Growth hormone pulse (High benefit) → appetite surge (Medium benefit) → body composition/lean mass (Low benefit), matching the ER’s benefit tiers at lines 153, 167, and 175. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects are present. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans populated; values 30–45 min, 20–30 min, and 8–12 weeks all appear in ER line 451. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides an explicit “Time to effect” bullet at line 451. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All ten entries correspond to the ER benefit headings at lines 153–213. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated at QRS lines 531–547. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER heading alone; the ER’s Magnitude paragraphs, p-values, confidence intervals, and single-institution caveats are entirely absent. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses occur in any benefits span. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All eleven entries correspond to the ER risk headings at lines 237–303. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated at QRS lines 609–626. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER heading alone; the ER’s Magnitude data (2.7 kg vs 0.8 kg, cortisol 56.0 ± 31.0 ng/mL) and mechanistic paragraphs are absent. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses occur in any risks span. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers contain items. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the ER Monitoring Protocol & Defining Success biomarker table at lines 479–489. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER biomarkers present in ER order: IGF-1, IGF binding protein 3, fasting glucose, fasting insulin, hemoglobin A1c, morning cortisol, prolactin, TSH and free T4, apolipoprotein B — with targets and rationales carried verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Populated at QRS lines 758–761, condensing the ER’s baseline and ongoing-cadence paragraphs (lines 475–477) including the 2–3 week off-period retest. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the ER “Qualitative markers” list at lines 493–501. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All nine ER qualitative markers present and in ER order: hunger, sleep quality, morning puffiness/ankle swelling, hand numbness, joint aching, waist circumference, recovery quality, afternoon energy stability, libido and cycle regularity. |
Issues 07/08/2026 08:47
Pass rate 100.00%. No issues found.